Patents by Inventor Phillip D. Cook

Phillip D. Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7807653
    Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: October 5, 2010
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
  • Patent number: 7598230
    Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: October 6, 2009
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
  • Patent number: 7285658
    Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: October 23, 2007
    Assignee: Biota, Inc.
    Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Nicholas A. Boyle, Janet M. Leeds, Jennifer L. Brooks, Marija Prhavc, Maria Eugenia Ariza, Patrick C. Fagan, Yi Jin, Vivek K. Rajwanshi, Kathleen D. Tucker
  • Publication number: 20040023901
    Abstract: The present invention relates to novel nucleoside 5′-monophosphate mimics, which contain novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, anticancer, and immunomodulatory agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Application
    Filed: February 28, 2003
    Publication date: February 5, 2004
    Inventors: Phillip D. Cook, Guangyi Wang, Thomas W. Bruice, Vasanthankumar Rajappan, Kandasamy Sakthivel, Kathleen D. Tucker, Jennifer L. Brooks, Janet M. Leeds, Maria Eugenia Ariza, Patrick C. Fagan
  • Publication number: 20030065146
    Abstract: Novel ethylene glycol compounds bearing various functional groups are used to prepare oligomeric structures. The ethylene glycol monomers can be joined via standard phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.
    Type: Application
    Filed: June 3, 2002
    Publication date: April 3, 2003
    Inventors: Phillip D. Cook, Oscar L. Acevedo, Peter W. Davis, David J. Ecker, Normand Hebert
  • Patent number: 6448373
    Abstract: Novel ethylene glycol compounds bearing various functional groups are used to prepare oligomeric structures. The ethylene glycol monomers can be joined via standard phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.
    Type: Grant
    Filed: January 11, 1994
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Oscar L. Acevedo, Peter W. Davis, David J. Ecker, Normand Herbert
  • Patent number: 6271357
    Abstract: Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds contain a selected sequence of nucleosidic bases or other reactive groups that are covalently bound through nitrogen-containing linear, hairpin, dumbbell, and circular shaped tethers.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: August 7, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Yogesh S. Sanghvi
  • Patent number: 5783682
    Abstract: Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds contain a selected sequence of nucleosidic bases or other reactive groups that are covalently bound through nitrogen-containing linear, hairpin, dumbbell, and circular shaped tethers.
    Type: Grant
    Filed: January 11, 1994
    Date of Patent: July 21, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Yogesh S. Sanghvi
  • Patent number: 5637684
    Abstract: Compounds are provided having the structure: ##STR1## wherein the L groups are spanner or linker units, the Y and T group are functional groups for interacting with target molecules of interest, the X groups are oxygen or sulfur and the E groups are H, conjugate groups or intermediate groups used during the synthesis of the compounds are prepared using H phosphonate type chemistry wherein the functional groups are added during an oxidization step.
    Type: Grant
    Filed: February 23, 1994
    Date of Patent: June 10, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Oscar Acevedo, Normand Hebert
  • Patent number: 5635488
    Abstract: Sequence-specific phosphorothioate oligonucleotides comprising nucleoside units which are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. Such sequence-specific phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis. Sequence-specific phosphorodithioate oligonucleotides are also provided. Such sequence-specific phosphorodithioate oligonucleotides are prepared by chemical synthesis. They are especially well suited as diagnostics, therapeutics and research reagents.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 3, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Glenn Hoke
  • Patent number: 5632898
    Abstract: Simple and efficient methods for scavenging excess electrophiles from a reaction mixture are provided utilizing addition of water soluble nucleophiles or solid support bound nucleophiles. Resulting addition products are removed from reaction mixtures through convenient separation techniques.
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: May 27, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Michael E. Jung, Phillip D. Cook, Andrew M. Kawasaki
  • Patent number: 5623065
    Abstract: Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.
    Type: Grant
    Filed: June 21, 1994
    Date of Patent: April 22, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Brett P. Monia
  • Patent number: 5623070
    Abstract: Oligonucleotide-mimicking macromolecules that have improved nuclease resistance are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligonucleotides with three or four atom linking groups provide unique oligonucleotide-mimicking macromolecules that are useful in regulating RNA expression and in therapeutics. Methods of synthesis and use also are disclosed.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: April 22, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Yogesh S. Sanghvi
  • Patent number: 5620963
    Abstract: Sequence-specific phosphorothioate oligonucleotides comprising nucleoside units which are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. Such sequence-specific phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis. They are especially well suited as diagnostics, therapeutics and research reagents in instances of cancer mediated by PKC-.alpha..
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 15, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Glenn Hoke
  • Patent number: 5618704
    Abstract: Methods for preparing oligonucleotide analogs which have improved nuclease resistance and improved cellular uptake are provided. In preferred embodiments, the methods involve radical coupling of 3'- and 5'-substituted or 5'- and 3'-substituted nucleosidic synthons.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: April 8, 1997
    Assignee: ISIS Pharmacueticals, Inc.
    Inventors: Yogesh S. Sanghvi, Phillip D. Cook
  • Patent number: 5614621
    Abstract: Synthetic processes are provided wherein substituted silylalkyl phosphoramidites serve as coupling reagents for preparing phosphate, phosphorothioate, and other phosphorous-containing covalent linkages. Also provided are synthetic intermediates useful in such processes.
    Type: Grant
    Filed: July 29, 1993
    Date of Patent: March 25, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Vasulinga T. Ravikumar, Dennis Mulvey, Douglas L. Cole, Phillip D. Cook
  • Patent number: 5610289
    Abstract: Therapeutic oligonucleotide analogues which have improved nuclease resistance and improved cellular uptake are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligomers with four atom linking groups forms unique di- and poly- nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: March 11, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Yogesh S. Sanghvi, Jean J. Vasseur, Francoise Debart
  • Patent number: 5607923
    Abstract: Sequence-specific phosphorothioate oligonucleotides comprising nucleoside units which are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. Such sequence-specific phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis. They are especially well suited as diagnostics, therapeutics, and research reagents in instances of retinitis caused by cytomegalovirus.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 4, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Glenn Hoke
  • Patent number: 5608046
    Abstract: Tetrahydrofuranyl compounds are provided that are functionalized to include pendant conjugate groups, and which are useful in diagnostic assays and as research reagents. Novel intermediates for the synthesis of the compounds are also provided.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: March 4, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip D. Cook, Kelly Teng
  • Patent number: 5602240
    Abstract: Oligonucleotide analogs are provided wherein phosphodiester inter-sugar linkages are replaced with four atom linking groups. Such linking groups include NR--C(O)--CH.sub.2 --CH.sub.2, NR--C(S)--CH.sub.2 --CH.sub.2, CH.sub.2 --NR--C(O)--CH.sub.2, CH.sub.2 --NR--C(S)--CH.sub.2, CH.sub.2 --CH.sub.2 --NR--C(O)--R--CH.sub.2, and CH.sub.2 --C(S)--NR--CH.sub.2. Methods for preparing and using these oligonucleotide analogs are also provided.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: February 11, 1997
    Assignees: Ciba Geigy AG., Isis Pharmaceuticals, Inc.
    Inventors: Alain De Mesmaeker, Jacques Lebreton, Adrian Waldner, Phillip D. Cook